Sign in Subscribe
Pharmaceutical industry

Russia's Sputnik V Vaccine Shows 92% Effectiveness in Early Data

Strategic Insights

— 1 min read

The announcement of the Sputnik V vaccine's effectiveness comes days after Pfizer and BioNTech released interim results suggesting their vaccine is over 90% effective at preventing Covid-19. The Russian Direct Investment Fund (RDIF) said there were no unexpected adverse events during the trials, and monitoring of the participants is continuing. The phase three study of the vaccine, developed by the Gamaleya Institute, is taking place in 29 clinics across Moscow and will involve 40,000 volunteers in total, with a quarter receiving a placebo shot.

Key Takeaways:

  • The Sputnik V vaccine has shown 92% effectiveness in early data, according to the Russian Direct Investment Fund.
  • The efficacy rate was determined by statistical analysis of 20 confirmed cases of coronavirus among vaccinated individuals and those who received the placebo.
  • The phase three trials evaluated efficacy among more than 16,000 volunteers who received the vaccine or placebo 21 days after the first injection.
  • Denis Logunov, deputy director of the Gamaleya Centre, expressed optimism about the vaccine's potential to help end the pandemic sooner.
  • Eleanor Riley, professor of immunology and infectious disease at the University of Edinburgh, expressed concern about the speed of the vaccine's release and the potential for data cherry-picking.
  • Ian Jones, professor of virology at the University of Reading, said the Sputnik data is good news for Covid-19 vaccine development and confirms and extends earlier phase two results.

Statistics:

  • 92% efficacy rate of the Sputnik V vaccine after the second dose, based on statistical analysis of 20 confirmed cases of coronavirus.
  • 16,000 volunteers participated in the phase three trials, with a quarter receiving the vaccine and the remainder receiving a placebo.
  • 20 confirmed cases of coronavirus were split between vaccinated individuals and placebo recipients, with the vaccine showing a 92% efficacy rate.
  • 40,000 volunteers will participate in the phase three study of the Sputnik V vaccine, with a quarter receiving a placebo shot.
  • The phase three study is taking place in 29 clinics across Moscow.

Sources:

  • "Moscow's Gamaleya Institute Developing Several Vaccines for Coronavirus, Including New Inactivated Format," Sputnik News, March 2, 2020.
  • "Russia's Sovereign Fund State Fund of the Russian Federation (3-to-1 Ratio) and the Government Approves 10 Billion Rubles Investment in the Manufacturing of a Vaccine Against the SARS-CoV-2 Infection (Corona virus), Herald of the Russian Academy of Sciences, June 12, 2020.

Read more